News | ECG | February 11, 2022

Philips Introduces First At-Home, 12-Lead ECG Integrated Solution for Decentralized Clinical Trials

Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials.

Philips, a global leader in health technology, announced the introduction of the industry’s first full-service, at-home, 12-lead electrocardiogram (ECG) solution for use in decentralized clinical trials.

The solution’s innovative body-worn patch ensures compliant 12-lead ECG placement and near real-time, highly secure data transmission without the need for recurring site visits, onsite technician, or home nurses.


February 11, 2022 – Philips, a global leader in health technology, announced the introduction of the industry’s first full-service, at-home, 12-lead electrocardiogram (ECG) solution for use in decentralized clinical trials. The clinical-grade solution is the most advanced patient-centric ECG offering within the company’s cardiac monitoring portfolio, pairing data readings comparable to clinical, site-based ECGs with Philips leading cloud-based data collection and analysis services. This latest addition to Philips’ digitally enabled suite of monitoring solutions helps to drive innovation across the care continuum and support the decentralized clinical trial space.

Patient attrition is one of the biggest issues faced by clinical trial sponsors seeking regulatory approval for new therapies. Attrition over the course of a study can reduce the quality of its findings and can lead to longer, more expensive trials that require higher than optimal recruiting rates to compensate. Voluntary patient withdrawal is often tied to disease progression or the prolonged inconvenience of adhering to protocol regimens and repetitive site visits [1]. By offering the consistent and reliable standards of a 12-lead ECG in the comfort and convenience of a patient’s home, Philips at-home ECG solution aims to improve trial recruitment, compliance and patient retention by reducing the need for and burden of site visits.

“Our customers are seeking solutions that will help them to address key challenges that can stand in the way of extracting meaningful insights from their clinical trials,” said Andy Broadway, General Manager of Ambulatory Monitoring and Diagnostics at Philips. “Our growing portfolio of remote monitoring solutions help to curb patient attrition by reducing the amount of site visits required during the trial period, helping to improve both the quality of the outcome and the patient experience overall.”

Leveraging PCA 500 ECG patch data recording technology, the at-home solution allows clinical trial participants to record data with quality comparable to site-based ECGs at home. The solution’s innovative body-worn patch ensures compliant 12-lead ECG placement and near real-time, highly secure data transmission without the need for recurring site visits, onsite technician, or home nurses.

Philips offers a complete range of clinically validated ambulatory cardiac diagnostics and monitoring services and associated expertise to its cardiac care portfolio, including its BioTel Research capabilities that have already supported more than 2,000 clinical trials in 72 countries. These comprehensive offerings provide industry-leading technology and data management that streamlines the clinical trials process and ensures optimal performance. The at-home, 12-lead ECG solution is now available in select markets across North America, Europe and Asia.

[1] Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer. 2013;119(5):1098-1105. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568443//PMC3568443/

For more information: https://www.usa.philips.com/healthcare


Related Content

News | ECG

November 21, 2023 — AccurKardia, an ECG-led diagnostics software company, announced a multi-year agreement with Lucem ...

Home November 21, 2023
Home
News | ECG

October 13, 2023 — InfoBionic, Inc. today announced that it received 510(k) clearance from the U.S. Food and Drug ...

Home October 13, 2023
Home
News | ECG

October 13, 2023 — The newly MDR-certified Cardiomatics solution is accurate, fast and easy-to-use AI-based standalone ...

Home October 13, 2023
Home
News | ECG

September 26, 2023 — Heart Test Laboratories, Inc., an AI-powered medical technology company focused on transforming ...

Home September 26, 2023
Home
News | ECG

September 6, 2023 — Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ...

Home September 06, 2023
Home
News | ECG

August 15, 2023 — Clario, a healthcare research technology company that delivers leading endpoint technology solutions ...

Home August 15, 2023
Home
News | ECG

July 27, 2023 — Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence (AI)-based medical ...

Home July 27, 2023
Home
News | ECG

June 21, 2023 — Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device ...

Home June 21, 2023
Home
News | ECG

June 19, 2023 — AliveCor, a global leader in personal electrocardiogram (ECG) technology, has announced a groundbreaking ...

Home June 19, 2023
Home
News | ECG

June 9, 2023 — Mount Sinai researchers have developed an innovative artificial intelligence (AI) model for ...

Home June 09, 2023
Home
Subscribe Now